Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novan, Inc. - Common Stock (NQ:NOVN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novan, Inc. - Common Stock

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
From Novan, Inc.
Via GlobeNewswire
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
From Novan, Inc.
Via GlobeNewswire
Novan Focuses Strategic Direction and Announces Restructuring
From Novan, Inc.
Via GlobeNewswire
Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Novan, Inc.
Via GlobeNewswire
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
From Novan, Inc.
Via GlobeNewswire
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹
From Novan, Inc.
Via GlobeNewswire
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
Live moderated webcast with members of the Novan management team and dermatological key opinion leader, Dr. Jeffrey Sugarman on Tuesday, April 25th at 2:00 PM ET 
From Novan, Inc.
Via GlobeNewswire
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update
From Novan, Inc.
Via GlobeNewswire
Novan to Report Full Year 2022 Financial Results on March 30, 2023
From Novan, Inc.
Via GlobeNewswire
Novan Announces Closing of $6.0 Million Registered Direct Offering
From Novan, Inc.
Via GlobeNewswire
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
Presentation with live webcast today, March 14th at 10:40 AM ET 
From Novan, Inc.
Via GlobeNewswire
Novan Announces $6.0 Million Registered Direct Offering
From Novan, Inc.
Via GlobeNewswire
Novan Moves Forward with Unified Corporate Branding
From Novan, Inc.
Via GlobeNewswire
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
From Novan, Inc.
Via GlobeNewswire
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Thursday, January 19th at 12:00 PM ET 
From Novan, Inc.
Via GlobeNewswire
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Via ACCESSWIRE
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
From Novan, Inc.
Via GlobeNewswire
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan
From Novan, Inc.
Via GlobeNewswire
EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement
From Novan, Inc.
Via GlobeNewswire
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
From Novan, Inc.
Via GlobeNewswire
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Novan, Inc.
Via GlobeNewswire
Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
From Novan, Inc.
Via GlobeNewswire
EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
Research shows PAD (Polyaphron Dispersion) Technology™ leads to more efficient delivery of Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) than CAL/BDP topical suspension 
From Novan, Inc.
Via GlobeNewswire
EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®
Data collected shows importance of treatment formulation characteristics and speed of improvement in psoriasis symptoms to patient treatment adherence 
From Novan, Inc.
Via GlobeNewswire
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
From Novan, Inc.
Via GlobeNewswire
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating... 
From JTC Team, LLC
Via AccessWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.